-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2369 When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Program: Oral and Poster Abstracts
Session: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality)
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Marina Gomez-Llobell, MD1*, Roni Shouval, MD, PhD1,2, Samantha Brown3*, Noa Golan Accav4,5*, Sean M. Devlin, PhD3*, Magdalena Corona, MD, PhD1*, Kai Rejeski, MD1, Alfredo Rivas-Delgado, MD, PhD6, Alejandro Luna, MD, PhD1*, Efrat Luttwak, MD6, Sandeep S. Raj, MD1, Mohammad Alhomoud, MD1, Ronit Marcus, MD7,8*, Avichai Shimoni, MD9,10*, Shimrit Ringelstein-Harlev11*, Alexander P. Boardman, MD2,6*, Parastoo B Dahi, MD2,12*, Richard J. Lin, MD, PhD2,13, Michael Scordo, MD2,12, Lorenzo Falchi, MD14, Gunjan L. Shah, MD2,15, Maria Lia Palomba, MD2,6, Gilles Salles, MD, PhD2,6, Jae H. Park, MD2, Ofrat Beyar-Katz, MD, PhD16,17*, Abraham Avigdor, MD18,19,20 and Miguel Angel Perales, MD1,2,14,15,21,22,23

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
2Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
3Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
4Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel aviv, Israel
5School of Medicine, Faculty of Medical and health Sciences, Aviv University, Tel-Aviv, Israel
6Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
7Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Ramat Gan, Israel
8School of Medicine, Faculty of Medical and health Sciences,Aviv University, Tel Aviv, Israel
9Division of Hematology and Bone Marrow Transplantation Department, Chaim Sheba Medical Center, Tel-Aviv, Israel
10School of Medicine, Faculty of Medical and health Sciences,Aviv University, Tel-Aviv, Israel
11Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus;The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel
12Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY
13Adult BMT Service; Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
14Memorial Sloan Kettering Cancer Center, New York, NY
15Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
16Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus; The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel
17Rambam Health Care Campus;The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel
18Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Aviv, Israel
19School of Medicine, Faculty of Medical and health Sciences, Aviv University, Tel Aviv, Israel
20Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Ramat Gan, Israel
21Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
22Department of Medicine, Adult Bone Marrow Transplant Service, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center,, New York
23Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

Background: While response rates to CD19-targeted CAR T cell therapies in large B cell lymphoma (LBCL) are high, up to 60% of patients ultimately relapse or progress. Consequently, determining the optimal time point to define a cure following CAR-T therapy remains challenging. To address this, we performed serial evaluations of the risk of relapse after CAR-T, contingent on patients remaining disease-free at specific time points.

Methods: This retrospective multicenter study includes patients with LBCL treated with commercially available CD19 CAR-T products between April 2018 and June 2023. Primary endpoints were progression-free survival (PFS) and overall survival (OS) measured in patients who maintained a response from various landmarks after CAR-T infusion (Day 28, 3, 6, 12, 18, and 24 months). Response rate transitions were visualized using Sankey diagrams. Cox regression models were adjusted for age, NHL transformation, elevated vs. normal LDH, response at corresponding landmark time, CAR-T product, and bridging therapy to determine associations with PFS.

Results: We included 477 patients treated with Axi-cel (n=260, 55%), Tisa-cel (n=130, 27%), and Liso-cel (n=87, 18%). Patients were heavily pre-treated, with 79% having received >3 lines of therapy. Overall response rate (ORR) at Day 28 was 78%, with 50% achieving complete response (CR) and 28% partial response (PR). With a median follow-up of 18 months for Axi-cel, 34 months for Tisa-cel, and 12 months for Liso-cel, median PFS was 12 months for Axi-cel, 3.2 months for Tisa-cel, and not reached for Liso-cel.

Among patients in CR on day 28 (n=195), 1 and 2-year PFS from day 28 landmark was 64% and 53%, corresponding OS probability was 90% and 74%. Patients with a PR on day 28 (n=194) had lower PFS (1-year: 43%, 2-year: 40%) and OS (1-year 65%, 2-year 50%). Probabilities of 1 and 2-year PFS also varied by product in patients achieving response: Axi-cel (58%/52%), Tisa-cel (46%/35%), and Liso-cel (62%/57%).

For patients in CR at 3 months (n=173), PFS from the 3-month landmark was 76% at one year and 66% at two years, while the corresponding OS probability was 92% and 81%. By product, PFS probabilities at one year and two years were, respectively, Axi-cel (83% /74%), Tisa-cel (66% /46%), and Liso-cel (75%/69%).

For patients in CR at 6 months (n=148), the PFS from the 6-month landmark was 77% at one year and 64% at two years, while the corresponding OS probability was 89% and 81%. By product, PFS probabilities at one year and two years were, respectively, Axi-cel (81%/67%), Tisa-cel (66% / 49%), and Liso-cel (78%/78%).

After one year in CR (n=128), patients treated with Axi-cel and Liso-cel have PFS rates for the year following the 1-year landmark of 89% and 100%, respectively. In patients treated with Tisa-cel, 1-year PFS was lower (83%) and only patients in CR at 2 years had a PFS from the landmark increased to over 90%. However, 1 year OS probability from 1-year landmark remains above 90% for all products: Axi-cel (94%), Tisa-cel (96%), and Liso-cel (100%).

Finally, in a multivariable Cox regression model for PFS, elevated LDH levels before lymphodepletion were associated with an increased risk of loss of response at the day 28, 3 months and 6 months landmarks (HR 2.66 (95% CI: 1.84, 3.84), p < 0.001; 2.06 (95% CI: 1.12, 3.80), p = 0.024; 2,43(95% CI: 1,25,4,72), p = 0.011, respectively). From the 6-month landmark, Tisa-cel showed a higher risk of progression compared to Axi-cel (HR 3.58, 95% CI: 1.57-8.14; p = 0.009), while Liso-cel showed no significant difference (HR 1.23, 95% CI: 0.48-3.19) compared to Axi-cel.

Conclusion: In this large real-world analysis of the three commercially available products for LBCL, we provide a benchmark for data-driven conversations about long-term survival with patients in remission. Our findings indicate that with Tisa-cel, a longer remission duration of two years post-CAR-T is required to determine a high likelihood of cure.Notably, we find that patients maintaining remission at 1 year following Axi-cel and Liso-cel have a very low probability of relapse, underscoring their curative potential.

Disclosures: Rejeski: Pierre-Fabre: Other: Travel Support; BMS/CELGENE: Consultancy, Honoraria; Novartis: Honoraria; Kite/Gilead: Consultancy, Honoraria, Other: Travel Support, Research Funding. Boardman: Bristol Myers Squibb: Consultancy; OncLive: Honoraria; Cancer Study Group, LLC: Consultancy. Scordo: Sanofi: Research Funding; Kite - A Gilead Company: Consultancy; Medscape: Honoraria; MJH Life Sciences (Cancer Network): Honoraria; Miltenyi Biotec: Consultancy; IDEOlogy: Honoraria; Angiocrine Biosciences, Inc.: Research Funding; Amgen: Research Funding; Omeros Corporation: Consultancy, Research Funding. Falchi: ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; EvolveImmune: Consultancy; Roche: Consultancy, Research Funding; Genmab: Consultancy, Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Memorial Sloan Kettering Cancer Center: Current Employment; Genentech, Roche, Genmab, AbbVie, Innate, BeiGene: Research Funding; Genentech, Roche, Genmab, Abbvie, Sanofi, EvolveImmune: Honoraria; AbbVie, Genentech, ADC Therapeutics, Seagen, Ipsen: Membership on an entity's Board of Directors or advisory committees; Taylor Francis: Other: Journal Editor; Kaplan: Other: CME Presentation: Projects in Knowledge. Shah: Janssen, Amgen, Beyond Spring, BMS, GPCR, DSMB with ArcellX.: Research Funding. Palomba: Novartis: Consultancy; Synthekine: Consultancy; Cellectar: Consultancy; Bristo Meyer Squibb: Consultancy, Patents & Royalties: immediate family member. Salles: AbbVie: Consultancy, Research Funding; Genmab: Consultancy, Research Funding; Ipsen: Consultancy, Research Funding; Genentech/Roche: Consultancy, Research Funding; Merck: Consultancy; Janssen: Consultancy, Research Funding; Molecular Partners: Consultancy; Incyte: Consultancy; Kite/Gilead: Consultancy; BeiGene: Consultancy; BMS/Celgene: Consultancy; Nurix: Research Funding. Park: Autolus, Fate Therapeutics, Genentech, InCyte, Servier, Sobi, Takeda (Institution): Research Funding; Curocell: Current equity holder in publicly-traded company; Takeda: Consultancy; Adaptive Biotechnologies, Affyimmune, Allogene, Amgen, Artiva Biotherapeutics, Autolus, Bright Pharmaceutical Services, BMS, Caribou Biosciences, Curocell, Galapagos, Gilead Sciences, Intellia, In8Bio, Kite, Novartis, Pfizer, Servier, Sobi, Synthekine: Consultancy. Avigdor: TG Therapeutics: Consultancy; Ascentage: Consultancy, Honoraria, Speakers Bureau; Karyospharm: Research Funding; BeiGene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding, Speakers Bureau; Eli Lilly: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Speakers Bureau; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, accommodations, expenses, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau. Perales: Miltenyi Biotec Incorporated: Consultancy; Kite Pharmaceuticals: Consultancy, Research Funding; Novartis: Consultancy; Sanofi S.A.: Consultancy; Incyte: Consultancy, Research Funding; Celgene: Consultancy; Jazz Pharmaceuticals: Consultancy; Nektar Therapeutics: Consultancy; ADC Therapeutics: Consultancy; Adicet: Consultancy; Allogene: Consultancy, Research Funding; Caribou Biosciences: Consultancy; ImmPACT Bio: Consultancy; Karyopharm: Consultancy; Merck: Consultancy; OrcaBio: Consultancy; VectivBio AG: Consultancy; NexImmune: Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Omeros: Current equity holder in publicly-traded company; OrcaBio: Current equity holder in publicly-traded company; Miltenyi Biotec: Consultancy, Research Funding; Sellas Life Sciences: Research Funding; Bristol-Myers Squibb: Consultancy.

*signifies non-member of ASH